| Document |
Document Title |
|
WO/2021/039791A1 |
The present invention addresses the problem of providing a novel medicine that is effective for preventing or treating angiogenesis-related diseases. As a means for solving the problem, produced is a medicinal composition that comprise...
|
|
WO/2021/031999A1 |
The present invention belongs to the field of medicine, and specifically relates to a prodrug of mycophenolic acid and a method for preparation thereof. The structural formula thereof is as shown in formula I; in comparison with mycophen...
|
|
WO/2021/034850A1 |
The present invention provides aqueous in-situ gel ophthalmic formulations, each including water, difluprednate and a biocompatible polysaccharide, wherein a gel is formed in situ at physiological temperature with instant viscosity incre...
|
|
WO/2021/034080A1 |
The present invention relates to a composition for the prevention or treatment of allergic diseases or atopic dermatitis comprising Carvone as an active ingredient. The composition comprising Carvone of the present invention as an active...
|
|
WO/2021/034267A1 |
The invention relates to formulations and methods of using formulations of topical preparation of diaminophenothiazine compounds such as 3,7-bis(dimethylamino)phenothiazin-5-ium chloride in the prevention and/or treatment of peripheral n...
|
|
WO/2021/032073A1 |
It relates to aqueous ophthalmic formulations containing 0.01%-5% by weight of cyclosporine which exists in the form of micelles having a particle size not greater than 20nm, and methods of making and using such formulations.
|
|
WO/2021/034082A1 |
The present invention relates to a composition for preventing or treating allergic diseases or atopic dermatitis, comprising ocimene or camphor as an active ingredient. The composition comprising ocimene or camphor as an active ingredien...
|
|
WO/2021/033599A1 |
[Problem] The purpose of the present invention is to provide a dynamic visual acuity improving agent capable of effectively improving dynamic visual acuity. [Solution] By using, as an active ingredient of a dynamic visual acuity improvin...
|
|
WO/2021/033154A1 |
Disclosed herein are pharmaceutical compositions and methods for the treatment of anterior blepharitis and posterior blepharitis which may be of primary origin and not secondary to other factors such as infections, infestations or rosace...
|
|
WO/2021/028456A1 |
The invention relates to three-dimensional tissue units which are hollow and which comprise, when organised about an internal opening, at least one layer of living human retinal pigment epithelium cells which are differentiated, the basa...
|
|
WO/2021/027722A1 |
Disclosed is an immunomodulator, and specifically disclosed are a compound that inhibits IL-17A and the use thereof as an immunomodulator in the preparation of a drug. Disclosed is the use of a compound as shown in formula I or a stereoi...
|
|
WO/2021/027721A1 |
Disclosed is an immunomodulator. The present invention specifically relates to a compound as represented by formula I or a stereoisomer of same or a pharmaceutically acceptable salt thereof. Experiments show that the compound provides ex...
|
|
WO/2021/026653A1 |
The present disclosure concerns the use of a cholinesterase inhibitor for improving binocular function and, in some embodiments, lessening an imbalance of binocular vision by promoting fusional ability and/or reducing interocular inhibit...
|
|
WO/2021/029238A1 |
Provided are: an agent for preventing or treating Th17 cell-induced disease, the agent containing as an active ingredient an agonist that exhibits agonist activity against adiponectin receptors 2 (PAQR2) without exhibiting agonist activi...
|
|
WO/2021/027306A1 |
Disclosed is a conjugate obtained by condensing dihydroartemisinin and a steroid, as represented by the following general formula (I), or an isomer, pharmaceutically acceptable salt, or prodrug molecule thereof; wherein the hydroxy group...
|
|
WO/2021/030451A1 |
The invention provides auricular dosage forms containing glycerol as a permeation enhancer for therapeutic agent delivery to the inner ear via the round window membrane. Exemplary conditions that may be treated and/or prevented using the...
|
|
WO/2021/027724A1 |
Provided in the present invention is an immunomodulator, wherein same falls within the field of medicinal chemistry. The immunomodulator is a compound as shown in formula I, or a stereoisomer thereof, or a salt thereof, or a solvate ther...
|
|
WO/2021/028365A1 |
The present invention relates to a stable crystalline polymorphic form of 6-fluoro-9- methyl-9H-β-carboline of formula (I) a method for preparation of said crystalline polymorphic form of 6-fluoro-9-methyl- 9H-β-carboline, and a pharma...
|
|
WO/2021/030452A1 |
The invention provides auricular dosage forms containing alkyl glycosides or sucrose fatty esters permeation enhancers for therapeutic agent delivery to the inner ear via the round window membrane. Exemplary conditions that may be treate...
|
|
WO/2021/027729A1 |
The present invention relates to an immunomodulator, in particular, to a compound as represented by formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof. Experiments show that the compound has good IL-17A inhi...
|
|
WO/2021/023804A1 |
The current invention relates to antibodies which bind to VEGF and ANG2 for use in the treatment of ocular vascular diseases such as neovascular AMD (nAMD) (also known as choroidal neovascularization [CNV] secondary to age-related macula...
|
|
WO/2021/025618A1 |
The present disclosure provides a use of an osmolyte in the manufacture of a medicament treating protein aggregation related disorders, specifically provides a use of an osmolyte in the manufacture of a medicament treating TGFBI corneal ...
|
|
WO/2021/024141A1 |
Provided herein is a method of preventing or treating diseases and disorders associated with tissue damages using an MST1/2 protein kinase inhibitor. The MST1/2 protein kinase inhibitor may be administered in its prodrug or salt forms. A...
|
|
WO/2021/023915A1 |
Antibiotic for use in a method comprising systemically administering a photosensitive antibiotic to a subject having a microbial infection in a target tissue to provide a blood plasma concentration of the antibiotic in the subject; allow...
|
|
WO/2021/025129A1 |
The present invention pertains to an ophthalmic composition which is for promoting tear secretion and contains 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-
diazaspiro[3.4]octane-1-yl]-3-oxopropanenitrile or a salt thereof.
|
|
WO/2021/017475A1 |
Disclosed is an ophthalmic pharmaceutical composition containing a cyclosporine, a preparation method and use thereof. The ophthalmic pharmaceutical composition expressed by weight percentages comprises 0.01%-0.5% of a cyclosporine, 0.2%...
|
|
WO/2021/021674A1 |
Provided herein are compositions that include a single nucleic acid vector or two different nucleic acid vectors, and the use of these compositions to treat hearing loss in a subject.
|
|
WO/2021/020535A1 |
Provided is a pharmaceutical composition that can be otically administered without a complicated procedure, and that has the function of retaining and gradually releasing a medication within the ear. The pharmaceutical composition for ot...
|
|
WO/2021/022215A1 |
The present disclosure provides compounds of the formula, wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated compli...
|
|
WO/2021/019464A1 |
Described herein are methods and pharmaceutical compositions for the prevention and/or treatment of visual impairment and vision loss, and more particularly to the use of DAN family BMP antagonist(s) for the prevention of ocular neovascu...
|
|
WO/2021/020252A1 |
Provided is a continual drug release device that can be implanted and can be replenished with drugs, the drug release device achieving drug delivery such that the drug release rate is controllable. This drug release device configured t...
|
|
WO/2021/021717A1 |
Disclosed here is an adenosine derivative prodrug that can have reverse transcriptase inhibitor activity in vivo. This disclosure is also directed to a pharmaceutical composition comprising the adenosine derivative that can be used for t...
|
|
WO/2021/021699A1 |
Provided herein are compounds useful in the prevention or treatment of ferroptosis in a patient, and methods of preventing or treating ferroptosis, or a treating a condition or disease associated with ferroptosis, such as a patient havin...
|
|
WO/2021/018879A1 |
Peptides for use as senotherapeutic agents. The present invention refers to senotherapeutic agents comprising different peptides for use in the prevention or treatment of aging- associated diseases caused by the persistence and accumulat...
|
|
WO/2021/014348A1 |
The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the t...
|
|
WO/2021/013452A1 |
The present invention relates to the treatment of dry eye disease and particularly, although not exclusively, to the treatment of dry eye disease with a LINK_TSG6 polypeptide.
|
|
WO/2021/014014A1 |
The present invention relates to the therapeutic use of azasetron or an analogue thereof for treating and/or preventing a lesion in the central auditory nervous system (CANS). The inventors show that treatment of lesions in the CANS with...
|
|
WO/2021/014372A1 |
The present invention provides bromocriptine for use in treating eye diseases associated with elevated level of vascular endothelial growth factor (VEGF), increased vascular permeability and abnormal angiogenesis processes. The invention...
|
|
WO/2021/013065A1 |
The present invention relates to the field of tumor immunotherapy, and relates to a humanized anti-VEGF Fab antibody fragment. Disclosed in the present invention are a nucleic acid sequence encoding the antibody fragment (comprising heav...
|
|
WO/2021/015647A1 |
The invention relates to pharmacology, specifically to the preparation of compositions based on a serotonin receptor antagonist, which can be used in opthalmology, therapy and geriatrics. Eye drops containing a serotonin receptor antagon...
|
|
WO/2021/007654A1 |
The present disclosure provides antisense oligonucleotides, compositions, and methods that target a ABCA4 exon or intron flanking an exon, thereby modulating splicing of ABCA4 pre-mRNA to increase the level of wild type ABCA4 mRNA molecu...
|
|
WO/2021/009664A1 |
The present invention provides methods for treating treating meibomian gland dysfunction using liver X receptor (LXR) agonists.
|
|
WO/2021/008161A1 |
A drug for alleviating pseudomonas keratitis, characterized by comprising a β2-adrenergic receptor inhibitor having a structure represented by formula (I).
|
|
WO/2021/010303A1 |
Provided is a novel therapeutic agent for a disease caused by a dominant mutant gene (7). The therapeutic agent according to the present invention comprises a donor DNA (20) that contains a polynucleotide having the following sequences (...
|
|
WO/2021/009623A1 |
Liquid formulation including a photo-sensitizing agent and an oxidizing agent, in particular for the treatment of eye disorders.
|
|
WO/2021/006603A1 |
The present invention relates to a novel pharmaceutical composition for treating allergic diseases and, more particularly, to a pharmaceutical composition for treating allergic diseases, comprising as active ingredients: a) an FcεRIα p...
|
|
WO/2021/006856A1 |
A medicine in the form of eye drops contains a bioflavonoid-based active ingredient, excipients and water for injection, wherein the bioflavonoid is dihydroquercetin, and the excipients are L-arginine amino acid, polyvinylpyrrolidone wit...
|
|
WO/2021/005497A1 |
Methods for the treatment and prevention of diseases and disorders associated with cortical spreading depression by administering a CGRP antagonist, a Clostridial derivative or combination thereof are described.
|
|
WO/2021/007474A1 |
Provided herein are compounds, for example, a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or...
|
|
WO/2021/007578A1 |
Opthalmic compositions are disclosed and described herein. In some embodiments, an ophthalmic composition can include as active agents a copper-containing agent and a secondary therapeutic agent in combination with a pharmaceutically acc...
|
